Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...
Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline ...
Pfizer (NYSE: PFE) is one of the world's largest pharmaceutical companies. It has a long history of innovation and success. Add in a lofty 6.6% dividend yield, and dividend investors are likely to ...
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...
Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.
While this year’s Super Bowl will be filled with more pharma ads than ever before, one big name will be missing from the roster. Pfizer, which has run ads during the Big Game for the past two years, ...
Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results